Key Takeaways
- Aleniglipron oral GLP‑1 produced up to 11.3% placebo‑adjusted weight loss at 36 weeks.
- Most common side effects were mild to moderate gastrointestinal events, decreasing over time with low discontinuation rates.
- No signs of liver injury or weight‑loss plateau emerged over the 36‑week study.
- Weight loss continued beyond 36 weeks in an open‑label extension, reaching over 16% in some arms.
What did the Phase 2b trial of Aleniglipron oral GLP‑1 show?
Aleniglipron oral GLP‑1 produced dose‑dependent reductions in body weight at week 36. Participants taking 45 mg lost about 8.2% more than placebo; 90 mg led to about 9.8%, and 120 mg delivered up to 11.3% placebo‑adjusted loss (P < 0.0001) Nature Med. By week 36, no clear weight‑loss plateau had emerged, and the open‑label extension showed continued loss up to about 16.2% by week 56 in some groups Nature.
How tolerable was Aleniglipron oral GLP‑1?
Gastrointestinal side effects—nausea, diarrhea, vomiting, constipation—occurred but were generally mild to moderate and became less frequent over time. Vomiting rarely returned after brief dose interruptions. Treatment‑related discontinuation across arms stayed around 10.4% PubMed. The study reported no drug‑induced liver injury in any participants PubMed.
Who participated in the aleniglipron study?
Researchers screened 406 adults and randomized 230 to the double‑blind Phase 2b ACCESS trial across 38 U.S. sites between October 28, 2024 and February 7, 2025. Participants had an average age of 49.8 years, BMI of about 39.5 kg/m², and 54% were female Nature.
What broader effects did the trial reveal?
Beyond weight, aleniglipron lowered HbA1c by up to ~0.36 percentage points at the highest dose versus essentially no change in placebo—starting from a mean baseline of 5.63% Nature. High‑sensitivity C‑reactive protein dropped substantially (28.8–46.4% reductions) compared with a 6.9% decrease on placebo Nature.
FAQ
What other benefits did aleniglipron oral GLP‑1 show?
It lowered HbA1c modestly (up to 0.36%) and reduced inflammation marker CRP by up to ~46%, beyond weight loss.
This article is for general information and is not medical advice. GLP-1 medications are prescription drugs that require clinical supervision — talk to a licensed healthcare provider before starting, stopping, or changing any treatment.